摘要 ：按照国家自然科学基金（以下简称科学基金）资助管理工作安排，现将2026年度科学基金项目申请和2025年资助期满项目结题等工作的有关事项通告如 下。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 关于2026年度国家自然科学基金项目申请与结题等有关事项的通告 国家自然科学基金委员会（以下简称自然科学基金委）坚持以习近平新时代中国特色社会主义思想为指导，全面贯彻党的二十大和二十届历次 全会精神，深刻领会习近平总书记关于基础研究的重要论述和指示批示精神，深入贯彻落实党中央、国务院决策部署，在中央科技委员会的领 导下，锚定2035年建成科技强国的战略目标，准确把握我国基础研究发展历史方位和科学基金新的使命定位，持续优化科学基金管理体系，切 实提升科学基金资助效能，为实现我国基础研究高质量发展和高水平科技自立自强贡献更大力量。 按照国家自然科学基金（以下简称科学基金）资助管理工作安排，现将2026年度科学基金项目申请和2025年资助期满项目结题等工作的有关 事项通告如下。 一、项目申请 (一) 项目申请接收。 国科金发计〔2026〕2号 1 ...

摘要 ： 近日，西安交通大学发布多批政府采购意向，仪器信息网特对其中的仪器设备品目进行梳理，统 计出27项仪器设备采购意向，预算总额达1.03亿元。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 近日，西安交通大学发布2 7项仪器设备采购意向，预算总额1 . 0 3亿元，涉及2 . 5MV快前沿脉冲 功率源、高分辨薄膜X射线衍射仪、等离子体刻蚀机、低能高速扫描电子显微镜、辉光放电质 谱离子源等，预计采购时间为2 0 2 5年7月~2 0 2 6年6月。 详细采购清单： 西安交通大学2 0 2 5年7月~ 2 0 2 6年6月 仪器设备采购 意向汇总表 | | | | 采 | | --- | --- | --- | --- | | 采购 | 需求概况 | 预算 | 购 | | 项目 | | 万元 | 时 | | | | | 间 | | | 采购项目名称：凝胶渗透色谱仪 采购数量：一台 交付时 | | 202 | | 凝胶渗 | 间：合同签订后180天内。 主要功能：氨基酸及多糖等天 | | 6 | | 透色谱 | 然高分子和水溶性高分子材 ...

Core Insights - The article discusses the performance and future outlook of Thermo Fisher Scientific, highlighting its strong market position and growth strategies for 2026 and beyond [3][19]. Financial Performance Analysis - No specific financial data is disclosed; the company plans to release its 2025 performance and 2026 guidance at the end of the month [4]. Key Growth Drivers - Revenue growth is driven by new product launches such as the Astral Zoom mass spectrometer and next-generation cryo-electron microscopes, alongside market share gains in the pharmaceutical and biotechnology sectors [5]. - Cost control measures through the PPI business system have led to exceeding a $300 million cost reduction target in 2025 [5]. - Capital deployment includes the acquisition of Solventum's purification and filtration business, the acquisition of Sanofi's production facility, and a $9 billion acquisition of Clario, with $3.6 billion returned to shareholders through buybacks and dividends [6]. Business Operations Overview - The pharmaceutical and biotechnology segment, which accounts for 56% of revenue, achieved mid-single-digit organic growth in the first nine months of 2025, outperforming industry standards [7]. - The bioproduction segment saw mid-teens organic growth, with strong demand for culture media and single-use technologies [7]. - The clinical research segment, as the second-largest CRO, experienced strong growth driven by accelerated drug development capabilities [7]. - The analytical instruments segment had low single-digit organic growth in 2025, with strong demand for core products like the Astral Zoom mass spectrometer [7]. Market Expansion - The U.S. market benefits from a trend of pharmaceutical reshoring, with the acquisition of Sanofi's New Jersey facility expanding sterile filling capacity [8]. - Increased confidence among pharmaceutical and biotechnology clients, along with improved funding in biotechnology, is driving industry demand growth [8]. R&D Investments and Outcomes - The company invests approximately $1.4 billion annually in R&D, launching several innovative products including the Astral Zoom mass spectrometer and scalable bioreactors [9]. Operational Efficiency - The PPI business system enhances cost reduction and productivity, successfully exceeding a $300 million cost reduction target in 2025 [10]. Future Outlook and Planning - Short-term goals for 2026 include executing growth strategies, launching impactful innovative products, and leveraging PPI and AI capabilities to enhance operational efficiency [12]. - Long-term strategies anticipate industry fundamentals improving, with organic growth expected to recover to over 7% by 2028 and beyond, driven by factors such as aging populations and advancements in life sciences [13]. Q&A Highlights - The company positions itself for 2026 as a year of significant opportunity, with a clear strategy and wise capital deployment [14]. - The CDMO business is expected to grow at a high single-digit rate, benefiting from reshoring and strong execution [16]. - The acquisition of Solventum is expected to enhance the product portfolio and contribute to mid-high single-digit organic growth [17]. - The basis for projected organic growth of 3%-6% in 2026-2027 is grounded in steady market improvements and market share growth [18]. Summary Remarks - The management emphasizes a focus on executing growth strategies through innovative products and operational efficiency improvements via the PPI business system and AI capabilities [19].

Core Viewpoint - The article emphasizes the strong policy support for the scientific instrument industry in China, with 20 provinces and municipalities incorporating relevant content into their 14th Five-Year Plan, focusing on original innovation and key core technology breakthroughs [1][2]. Provincial Summaries Guangdong Province - Strengthens original innovation and key core technology breakthroughs, enhancing strategic scientific support and establishing a robust laboratory system led by major labs [3][4]. Jiangsu Province - Continuously enhances original technology leadership, implementing unconventional measures to drive breakthroughs in key areas such as integrated circuits and high-end instruments [5]. Shandong Province - Aims to improve the resilience and safety of industrial supply chains, focusing on key technologies in advanced manufacturing and high-end instruments [6]. Tianjin Municipality - Strengthens collaborative innovation and industrial cooperation, aiming to build a world-class advanced manufacturing cluster [7]. Heilongjiang Province - Promotes original and integrated innovation in key technology areas, including quantum technology and artificial intelligence [9]. Jilin Province - Focuses on cultivating strategic emerging industries and achieving breakthroughs in key core technologies [10]. Liaoning Province - Enhances the integration of technology, industry, and finance, promoting key technology breakthroughs in various sectors [12]. Sichuan Province - Advances the integration of technological innovation and industrial innovation, improving the technology transfer system [14]. Chongqing Municipality - Develops emerging industries and future industries, fostering clusters in strategic sectors such as biomedicine and intelligent medical equipment [15]. Beijing Haidian District - Aims to build a high-end scientific instrument technology innovation center, focusing on overcoming key technological challenges [17]. Guangzhou City - Strengthens original innovation and key core technology breakthroughs, supporting the establishment of world-class laboratories [18]. Shenzhen City - Promotes original innovation and key core technology breakthroughs, focusing on various high-tech fields [19]. Hefei City - Enhances original innovation and key core technology breakthroughs, aiming for significant advancements in quantum technology and artificial intelligence [20][21]. Changsha City - Continues to enhance independent innovation capabilities, supporting the establishment of key national laboratories and innovation centers [22]. Zhengzhou City - Strengthens the role of enterprises in innovation, promoting a collaborative innovation ecosystem [23]. Lanzhou City - Focuses on original innovation and key core technology breakthroughs in various scientific fields [24]. Yinchuan City - Promotes the development of new industry clusters, focusing on advanced materials and renewable energy [25][26]. Guilin City - Aims for breakthroughs in key core technologies across various sectors, emphasizing the importance of original innovation [27]. Chengde City - Develops a diverse industrial structure, focusing on the integration of manufacturing and service sectors [28].

摘要 ： 三版《国家鼓励发展的重大环保技术装备目录》推动环境监测技术向精准化、智能化、多场景化 发展，覆盖大气、水、土壤、碳排放等领域。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 2020年-2025年，工业和信息化部、科学技术部、生态环境部等联合发布了三版《国家鼓励 发展的重大环保技术装备目录》 ，分别为《国家鼓励发展的重大环保技术装备目录（2020 年 版）》，共162项；《国家鼓励发展的重大环保技术装备目录（2023年版）》，共158项； 《国家鼓励发展的重大环保技术装备目录（2025 年版）》，共115项。 《国家鼓励发展的重大环保技术装备目录》是为了满足国家环境保护目标任务新要求，应对排 放标准持续提升、新建治污设施与升级改造规模扩大的现实需求，为精准治污、科学治污提供 装 备 支 撑 ， 适 配 大 气 、 水 、 固 废 、 土 壤 等 多 领 域 污 染 治 理 需 求 。 其 主 要 分 为 开 发 类 、 应 用 类、推广类三大类，大气污染防治、水污染防治、土壤污染修复、固废处理、环境监测专用仪 器仪表、环境污染 ...

Core Insights - The article discusses the 2025 provincial-level warning directory for newly purchased large scientific research facilities and instruments, highlighting the proactive measures taken by Shandong, Henan, and Guangxi provinces to avoid redundant purchases and enhance the efficiency of scientific instruments [1][2]. Summary by Sections Overview of the Warning Directory - The warning directory serves as an important basis for evaluating the purchase of large scientific research facilities and instruments valued at 500,000 yuan or more using provincial financial allocations [2][3]. Provincial Focus Areas - Each province has tailored its warning directory based on its specific scientific instrument layout and usage. For instance: - Henan Province lists seven types of instruments, including flow cytometers, PCR instruments, and laser confocal fluorescence microscopes [3]. - Shandong Province focuses on nine types, such as X-ray diffractometers and gas chromatographs [3]. - Guangxi Province emphasizes five types, including PCR instruments and DNA sequencers [7]. Detailed Instrument Distribution - The article provides detailed distribution data for various instruments across cities within the provinces: - In Henan, for example, there are 61 flow cytometers in Zhengzhou and 45 PCR instruments also in Zhengzhou [6]. - In Shandong, 56 X-ray diffractometers are located in Jinan, and 99 liquid chromatographs are also in Jinan [8][9]. Implications for Research Efficiency - The establishment of these directories signals a commitment to improving the utilization of scientific instruments and reducing financial waste associated with idle equipment [2][3].

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 " 国产好仪器 " 已 走过十多个年头，我们始终坚持以 "用户说好才是真的好"为不变的原则，以用户长期使用的真实 反馈为基础，从上千台候选仪器中，精心甄选出 400 多款品质卓越、性能稳定的国产佳品。 为了 更好地倾听用户的心声， "国产好仪器"再度升级， 通过更加深入和有针对性的用户调研 ，寻找满足 用户 需求 的 "国产好仪器"，助力 仪器 用户从海量信息中找到 "对"的产品！ 参与方式 ： 只要您使用过海报中的仪器产品，长按识别下方 仪器对应的 二维码参与调研就有机会获得奖品。 | 版 权 ： 本 文 部 分 素 材 源 自 网 络 ， 版 权 归 原 作 者 所 有 ， 观 点 代 表 作 者 本 人 ， 不 代 表 本 号立 场 | 转 载 ： 须 本 号 授 权 ， 请 联 系 主 编 | 来 源 ： 仪 器 信 息 网 | 责 编 ： 安 安 | 视 觉 ： 长 艳 柱 子 奖品设置 ： 凡参与调研的用户，即 有机会抽取 定制吸管玻璃杯 ；被认定为有效问卷的用户，还将获得 价值 ...

Core Viewpoint - The People's Bank of China has announced multiple financial policies to support the high-quality development of the real economy, particularly benefiting the scientific instrument industry through increased loan quotas and reduced interest rates [2][3]. Group 1: Financial Policy Changes - The central bank has increased the loan quota for technological innovation and equipment renovation by 400 billion, raising the total quota to 1.2 trillion [2]. - A new focus on supporting private small and medium-sized enterprises (SMEs) has been introduced, allowing them to benefit from the technological innovation and equipment renovation loan policies starting in 2026 [2]. - The central bank has decided to increase the agricultural and small business loan quota by 500 billion, with a total quota of 1 trillion specifically for private enterprises [2]. Group 2: Interest Rate Adjustments - Starting from January 19, 2026, the central bank will lower the re-lending and re-discount rates by 0.25 percentage points [3]. - The new rates will be 0.95%, 1.15%, and 1.25% for 3-month, 6-month, and 1-year agricultural and small business loans, respectively, with a re-discount rate of 1.5% [3]. - The policy also includes a commitment to provide up to 800 billion in funding support for carbon reduction initiatives [3].

摘要 ： 近日，中国科学院国家空间科学中心发布多批政府采购意向，仪器信息网特对其中的仪器设备品 目进行梳理，统计出13项仪器设备采购意向，预算总额达8908万元。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 近日， 中国科学院国家空间科学中心发布 1 3 项仪器设备采购意向，预算总额达 8 9 0 8 元 ， 涉 及全固态激光发射子系统 、法布里-珀罗干涉仪-配套设备、复杂瞬时突变及周期扰动力矩辨识 仪 、电磁场量子精密测量标定系统 、组合式大口径望远镜 等，预计采购时间为2 0 2 5 年 8 月 ~2 0 2 6年2 月。 详细采购清单： 中国科学院国家空间科学中心 2 0 2 5年8月~ 2 0 2 6年2月 仪器设备采购 意向汇总表 | | | 预算 | 采 购 | | --- | --- | --- | --- | | 采购项目 | 需求概况 | | | | | | 万元 | 时 | | | | | 间 | | 空间科学载荷先 | 项目计划采购离子束剖面应力消除设备 | | 202 6 | | | 等试验设备。为保证后续空间 ...

Core Insights - The article discusses the performance and strategic outlook of Illumina, emphasizing its leadership in the next-generation sequencing (NGS) market and the growth driven by clinical applications [3][4]. Financial Performance Analysis - In Q4 2025, revenue grew by 4% year-over-year at constant currency, with a 7% increase excluding the Chinese market [4]. - Earnings per share for Q4 2025 were projected between $1.27 and $1.30, with an annual EPS of approximately $4.76 to $4.79, reflecting over 15% growth [4]. - The company placed 95 units of the NovaSeq X series instruments in Q4 2025, with consumable sales driven by strong usage rates [4]. Key Growth Drivers - Revenue growth is primarily driven by the clinical market, with 60% of consumable revenue coming from clinical customers [6]. - Increased adoption of the NovaSeq X has doubled sequencing capabilities and boosted consumable demand [6]. - Customers are increasing sequencing intensity, necessitating a 15-fold volume growth for certain applications [6]. Business Operations Overview - The clinical market serves as the core growth engine, with strong demand in oncology, genetic diseases, and reproductive health [7]. - The academic research market shows signs of rebound but is expected to remain weak in 2026 [7]. Market Expansion - Global installed base exceeds 20,000 units, supporting a full lifecycle from early detection to routine clinical applications [8]. - The Chinese market faced sanctions but is gradually recovering post-sanction, with a current revenue contribution of 3% [8]. R&D Investments and Achievements - The launch of NovaSeq X enhances sequencing capabilities, with new technologies being integrated into existing platforms [9]. - Multi-omics products, including single-cell solutions and protein preparation systems, are being developed [9]. Operational Efficiency - The company has optimized end-to-end workflows, reducing total costs for customers by over 30% compared to alternatives [11]. - The NovaSeq X workflow has been simplified, improving laboratory efficiency [11]. Future Outlook and Plans - Short-term goals for 2026 include maintaining demand patterns from H2 2025 and focusing on clinical market growth [12]. - Long-term strategies involve expanding multi-omics capabilities and enhancing the Bio Insights business to drive digital drug discovery [13]. Q&A Highlights - Q4 performance exceeded expectations due to strong growth in markets outside China, with clinical market growth being a significant contributor [14]. - The transition to NovaSeq X is expected to have a reduced price impact in 2026 [15]. Market Health Status - The clinical market continues to grow, with 60% of consumable revenue derived from clinical applications [17]. - The academic research sector is anticipated to remain weak in 2026, but new technologies may drive long-term recovery [17]. Competitive Environment - Customers prioritize ecosystem and workflow integrity over price, with NovaSeq X offering advantages in flexibility and usability [18]. China Market Approval and Recovery - Post-sanction, instrument imports for OEM customers are allowed, with ongoing discussions to lift the "unreliable entity list" designation [19].